Filing Details

Accession Number:
0001012975-18-001046
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2018-08-27 18:12:28
Reporting Period:
2018-07-18
Accepted Time:
2018-08-27 18:12:28
Original Submission Date:
2018-07-20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1658247 Crinetics Pharmaceuticals Inc. CRNX () 4/A
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1164426 Joseph Edelman 51 Astor Place, 10Th Floor
New York NY 10003
No No Yes No
1224962 Perceptive Advisors Llc 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
1249675 Ltd Fund Master Sciences Life Perceptive 51 Astor Place, 10Th Floor
New York NY 10003
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-07-18 307,648 $21.30 307,648 No 4 P Indirect See footnotes
Common Stock Acquisiton 2018-07-20 1,880,305 $0.00 2,187,953 No 4 C Indirect See footnotes
Common Stock Acquisiton 2018-07-20 400,000 $17.00 2,587,953 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
No 4 C Indirect See footnotes
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2018-07-20 6,186,205 $0.00 1,880,305 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. This Form 4/A is being filed to report the July 18, 2018 purchase and correct the number of shares held by the Master Fund (as defined in Footnote 2).
  2. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
  3. The shares of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of 3.29 to 1 share, immediately prior to the consummation of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.